ArticleFrontiers in pharmacology2020

Feasibility Study of a Modified XELOX Adjuvant Chemotherapy for High-Recurrence Risk Patients With Operated Stage III Colon Cancer.

Jianhong Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.